Neuromity Therapeutics

Neuromity Therapeutics was a private U.S. biotech company focused on developing treatments for neurological and neuropsychiatric disorders using a deuterium-enabled chiral switching platform. Its lead disclosed program was NTY-184, a deuterium-stabilized S-bupropion being developed initially for major depressive disorder through a 505(b)(2)-oriented regulatory strategy. Available third-party company databases indicate the business was founded in 2021, based in the Boston area, and backed by early-stage venture financing. More recent company-tracking sources indicate the company is now out of business, and its former domain is no longer operating as a company website.